Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Nursing | Oncology | Radiology | Journal

Back to Journal Articles

Beta-Carotene Safe During Prostate Cancer Treatment

Last Updated: June 07, 2012.

 

After 10.5 years of follow-up, no significant increase in prostate cancer deaths or metastases

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The use of the antioxidant beta-carotene during radiation therapy treatment for prostate cancer is not associated with an increase in prostate cancer deaths or metastases, according to research published in the May issue of the International Journal of Radiation Oncology*Biology*Physics.

THURSDAY, June 7 (HealthDay News) -- The use of the antioxidant beta-carotene during radiation therapy treatment for prostate cancer is not associated with an increase in prostate cancer deaths or metastases, according to research published in the May issue of the International Journal of Radiation Oncology*Biology*Physics.

To investigate whether supplemental beta-carotene use during radiation therapy is associated with an increased risk of cancer death or metastases, Danielle N. Margalit, M.D., M.P.H., of the Harvard Radiation Oncology Program in Boston, and colleagues conducted a prospective, randomized study (as part of the larger Physicians' Health Study) involving 383 men receiving radiation therapy for prostate cancer. Participants were randomly allocated to receive beta-carotene (50 mg on alternate days) or placebo and were followed for a median of 10.5 years.

The researchers found that there was no significant difference in the risk of lethal cancer in the beta-carotene group compared with the placebo group (hazard ratio, 0.72; P = 0.24). The difference remained nonsignificant after adjustment for confounding variables. In the beta-carotene and placebo groups, the 10-year freedom from lethal prostate cancer was 92 and 89 percent, respectively.

"In summary, our data show that the use of supplemental beta-carotene during radiation therapy at doses commonly found in nutritional supplements is not associated with the risk of prostate cancer death or metastases," the authors write.

One of the authors disclosed financial ties to companies which manufacture nutritional supplements and to the California Strawberry Commission and Tomato Products Wellness Council.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: High-Fiber Diets Linked to Lower Visceral Fat in Teens Next: Intranasal Insulin Linked to Reduced Food Intake

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.